Acne Clinical Trial
Official title:
Double Blinded Vehicle Controlled Proof of Concept Study to Investigate the Recurrence of Inflammatory and Non-inflammatory Acne Lesions Using Tretinoin Gel (Microsphere) 0.04% in Male Patients Post Oral Isotretinoin Use
Verified date | February 2015 |
Source | Dermatrials Research |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Ethics Review Committee |
Study type | Interventional |
The use of topical retinoids is a mainstay and basis of early acne treatment to prevent the
progression to inflammatory lesions. Post oral isotretinoin, it is not uncommon for
non-inflammatory papules and comedones to recur. However, there has been no formal study to
look at the prevention of recurrence of these acne lesions post isotretinoin in a long term
basis. This may enhance the therapeutic options for post isotretinoin patients in order to
prevent recurrence of their disease.
Hypothesis Tretinoin microsphere 0.04% will prevent recurrence of acne lesions.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 2010 |
Est. primary completion date | December 2010 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: Subjects must fulfill all of the following criteria to be eligible for study admission: - Males aged between 18 and 45 years old who have successfully completed a treatment of acne with oral isotretinoin (Min 4 months/Maximum 6 months with an average of 5 months and a total of 120-150mg/kg/course). - Who can attend scheduled study follow-up visits at the outpatient dermatology clinic. - Agree to informed consent for participation in a study. - Agree to comply with the treatment and follow up procedures. Exclusion Criteria: - Patients who receive isotretinoin for condition other than acne vulgaris. - Patients who have been off isotretinoin for less than 30 days or more than 90 days at the time of enrollment of the study. - Patients who have used prescription topical acne treatment (tretinoin, benzoyl peroxide, topical antibiotics or any combination products) between the end of therapy of isotretinoin within 2 weeks of study enrollment or oral antibiotics of any type between the end of therapy of isotretinoin within 4 weeks of study enrollment and throughout the study. - Patients who have been previously diagnosed with an endocrinological disorder likely to cause acne such as genital/adrenal hyperplasia, adrenal tumors or any other hypo androgenetic state. - Patients who are using any of the systemic medications likely to cause or abate acne such as oral Dilantin or any other epileptic, Finasteride, Spironolactone or Flutamine, testosterone or dietary body-building protein powders. - Have any nodulo-cystic lesions at baseline. - Used topical corticosteroids on the face or systemic corticosteroids within the past 4 weeks. Use of inhaled, intra-articular, or intra-lesional steroids other than for facial acne is acceptable. - Are currently using any medication that in the opinion of the investigator may affect the action or evaluation of the study product or place the subject at undue risk. - Used abradants, facials, peels containing glycolic or other acids; masks, washes, or soaps containing BPO, salicylic acid, or sulfacetamide sodium; non-mild facial cleansers; moisturizers that contain retinol, salicylic acid, or a- or ß-hydroxy acids within the past 2 weeks. - Plan to use medications that are reported to exacerbate acne (e.g., mega-doses of certain vitamins, such as vitamin D [> 2000 IU per day] and vitamin B12 [> 1 mg/day], haloperidol, halogens [e.g., iodide and bromide], lithium, hydantoin, and phenobarbital), because these may impact efficacy assessments. Subjects who plan to use multivitamins, iron supplements and folate are acceptable. - Had a facial procedure (such as chemical or laser peel, microdermabrasion, blue light treatment, etc) performed by an esthetician, beautician, physician, nurse, or other practitioner, within the past 4 weeks or if it is planned to be performed during the conduct of the study. - Have a known hypersensitivity or have had previous allergic reaction to any of the active components or excipients of the study product. - Used any investigational therapy within the past 4 weeks, or currently participating in another clinical study. - Are currently abusing drugs or alcohol (drug screening not required). - Have a significant medical history of being immunocompromised. - Have other conditions that, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study. - Had any major illness within 30 days before the screening examination. - Currently are employees of R Vender, an investigator, or contract research organization (CRO) involved in the study, or an immediate family member (partner, offspring, parents, siblings or sibling's offspring) of an employee involved in the study. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Canada | Dermatrials Research | Hamilton | Ontario |
Lead Sponsor | Collaborator |
---|---|
Dermatrials Research | Johnson & Johnson |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary objectives-to assess the efficacy of Retin A micro 0.04% on the recurrence rate of acne post isotretinoin use compared to vehicle. | Six Months | No | |
Secondary | The percent change in lesion counts from baseline to week 16 and 24. | Six Months | No | |
Secondary | Proportion of subjects who have a Subject's Global | Assessment score of 0 or 1 at week 16 and 24 | No | |
Secondary | Proportion of subjects who have an ISGA score of 0 or 1 at week 16 and 24. | At week 16 and 24 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05097157 -
Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions
|
N/A | |
Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT04806594 -
Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar.
|
N/A | |
Recruiting |
NCT03465150 -
Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital
|
||
Completed |
NCT02250859 -
A Pharmacokinetic Study of Minocycline in Male and Female Volunteers
|
Phase 1 | |
Terminated |
NCT01193764 -
Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris
|
N/A | |
Completed |
NCT01206348 -
Combination Treatment for Moderate to Severe Acne
|
Phase 4 | |
Completed |
NCT00725439 -
An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne
|
Phase 2 | |
Completed |
NCT05640388 -
Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects
|
||
Completed |
NCT04873089 -
Efficacy Study of Cosmetic Product RV3278AET0943 Versus Non-treated Group in Adults With Oily and Acne Prone Skin
|
||
Recruiting |
NCT05941065 -
Study of Skin Balancing Gel Cream Safety and Influence of Skin Microbiome on Acne Prone Skin
|
N/A | |
Recruiting |
NCT06120452 -
A Clinical Trial to Evaluate the Effectiveness of an Acne Serum in Improving Facial Acne and Post-Acne Pigmentation
|
N/A | |
Completed |
NCT04300010 -
Blue Light Therapy of C. Acnes
|
Phase 4 | |
Recruiting |
NCT06202274 -
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
|
N/A | |
Completed |
NCT04559022 -
Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring
|
N/A | |
Terminated |
NCT02431494 -
Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris
|
N/A | |
Completed |
NCT05469880 -
Efficacy and Tolerance of Formula 609613 37 in Acneic Patients
|
N/A | |
Completed |
NCT02944461 -
Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris
|
Phase 4 | |
Completed |
NCT01951417 -
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
|
Phase 4 | |
Completed |
NCT01701024 -
Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne
|
Phase 3 |